| Cat.No. | Name | Information |
|---|---|---|
| M9872 | BS3 (bis(sulfosuccinimidyl)suberate) | BS3 (bis(sulfosuccinimidyl)suberate) is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). |
| M25284 | Brentuximab vedotin | Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma. |
| M24941 | Disitamab vedotin | Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity. |
| M24828 | Trastuzumab deruxtecan | Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. |
| M24608 | Polatuzumab vedotin | Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL). |
| M10408 | SuO-Val-Cit-PAB-MMAE | SuO-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB. |
| M10406 | N3-PEG3-vc-PAB-MMAE | N3-PEG3-vc-PAB-MMAE is a synthesized drug-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. |
| M10405 | Fmoc-Val-Cit-PAB-MMAE | Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADCs that consists of a ADC linker (Fmoc-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). |
| M10403 | MC-Val-Cit-PAB-MMAF | MC-Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC with antitumor activity by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable MC-Val-Cit-PAB. |
| M10402 | MC-GGFG-DX8951 | MC-GGFG-DX8951 is a drug-linker conjugate for ADC with antitumor activity by using DX8951 (a DNA topoisomerase I inhibitor), linked via the protease cleavable MC-GGFG linker. |
| M10400 | Val-Cit-PAB-MMAE | Val-Cit-PAB-MMAE is a MMAE derivative with a cleavable linker, which is useful to make MMAE conjugate for ADC. *The compound is unstable in solutions, freshly prepared is recommended |
| M10398 | Mc-MMAE | Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a drug-linker conjugate for ADC. *The compound is unstable in solutions, freshly prepared is recommended |
| M10397 | McMMAF | McMMAF is a protective group-conjugated MMAF. *The compound is unstable in solutions, freshly prepared is recommended |
| M10396 | Deruxtecan | Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. |
| M10199 | DSS Crosslinker (Disuccinimidyl suberate) | DSS Crosslinker (Disuccinimidyl suberate) is a non-cleavable, cell membrane permeable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). |
| M9879 | Sulfo-SMCC sodium | Sulfo-SMCC sodium is a commonly used hetero-bifunctional, noncleavable ADC crosslinker bearing N-hydroxysuccinimide (NHS) ester and maleimide groups to react with primary amines and sulfhydryl groups, respectively. |
| M9655 | CL2A-SN-38 | CL2A-SN-38 is a SN38 derivative with a peptide-linker which can easily react with antibody to form an ADC. |
| M9036 | DM1-SMCC | DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make ADC. |
| M5070 | Mc-Val-Cit-PABC-PNP | Mc-Val-Cit-PABC-PNP is a histone-cleavable peptide linker for antibody-drug couplings (ADCs) that can be used for the synthesis of ADCs such as Brentuximab vedotin. |
| M55738 | MC-SN38 | MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
